MedTrace Logo

Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor

NCT04149262 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 44

Last updated 2026-03-11

No results posted yet for this study

Summary

This is an exploratory, single-center retrospective cohort real-world study comparing safety and efficacy of Fiasp® versus NovoRapid® when used in the Medtronic MiniMed 640G system in pediatric subjects with Type 1 Diabetes Mellitus

Conditions

Interventions

DRUG

Fast-acting insulin aspart

Faster-acting insulin aspart used in insulin pump therapy in children and adolescents with type 1 diabetes mellitus during routine clinical care.

DRUG

Rapid-acting insulin analogues (insulin aspart or insulin lispro)

Rapid-acting insulin analogues used in insulin pump therapy in children and adolescents with type 1 diabetes mellitus during routine clinical care.

Sponsors & Collaborators

  • Aristotle University Of Thessaloniki

    lead OTHER

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-15
Primary Completion
2020-03-31
Completion
2023-02-15

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04149262 on ClinicalTrials.gov